Article Text


AB0026 Limphocytis expression of p-glycoprotein on peripheral blood in rheumatoid arthritis patients
  1. IR Kolosova,
  2. ER Polosukhina,
  3. AY Baryshnikov,
  4. GV Loukina,
  5. YA Sigidin
  1. Department of Clinical Pharmacology, Institute of Rheumatology, Moscow, Russia


Objectives To examine the expression of the multidrug resistance P-glycoprotein (P-gp 170) in patients with rheumatoid arthritis (RA). P-gp 170 is a pump molecule which decreases intracellular drug concentrations by increasing drug efflux from cells.

Methods Peripheral blood samples were obtained from 10 patients with active RA, and 8 normal subjects. The patients were treated with NSAIDs. Previous therapy with DMARDs was ineffective in 7 patients. 3 patients were not treated with DMARDs. Fluorescent flow cytometry on FACScan (Becfon Dichinson) was used to assess the expression of P-gp 170, with monoclonal antibodies (UIC2 PE, Immunotech).

Results The expression of P-gp on peripheral blood lymphocytes was elevated compared with control (29,6 ± 9,4% vs 1,6 ± 0,4%, P = 0,03). We did not observe any association between glycoprotein P expression and age, sex, disease activity, duration and stage of RA. The expression of P-gp 170 correlated with expression of antigens CD8 (r = 0,85) and CD71 (r = 0,83).

Conclusion The patient with RA showed increased expression of P-gp 170 as compared to the control. Further studies are needed to evaluate the potential implication of P-gp in drug resistance in RA.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.